<code id='FEFBDB84BF'></code><style id='FEFBDB84BF'></style>
    • <acronym id='FEFBDB84BF'></acronym>
      <center id='FEFBDB84BF'><center id='FEFBDB84BF'><tfoot id='FEFBDB84BF'></tfoot></center><abbr id='FEFBDB84BF'><dir id='FEFBDB84BF'><tfoot id='FEFBDB84BF'></tfoot><noframes id='FEFBDB84BF'>

    • <optgroup id='FEFBDB84BF'><strike id='FEFBDB84BF'><sup id='FEFBDB84BF'></sup></strike><code id='FEFBDB84BF'></code></optgroup>
        1. <b id='FEFBDB84BF'><label id='FEFBDB84BF'><select id='FEFBDB84BF'><dt id='FEFBDB84BF'><span id='FEFBDB84BF'></span></dt></select></label></b><u id='FEFBDB84BF'></u>
          <i id='FEFBDB84BF'><strike id='FEFBDB84BF'><tt id='FEFBDB84BF'><pre id='FEFBDB84BF'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:22175
          Portrait of Don Davis -- health policy coverage from STAT
          U.S. Representative Don Davis (D-N.C.) Wikimedia Commons

          WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.

          They found their perfect candidate in Rep. Don Davis, a Democrat representing a North Carolina district that includes parts of the state’s Research Triangle. He came to Washington in 2023, so didn’t vote on the original law. He received donations in 2023 from the political action committees for Gilead, Astellas, Genentech, Bayer, Pfizer, Novo Nordisk, GSK, Bristol Myers Squibb, BIO, Amgen, Boehringer Ingelheim, Merck, AbbVie, and Eli Lilly.

          advertisement

          “We must support the development of critical, life-sustaining medical treatments and cures,” Davis said in a written statement, and a spokesperson declined to elaborate. He is joined on the bill by Rep. Greg Murphy (R-N.C.) and Brett Guthrie (R-Ky.), the Energy and Commerce health subcommittee chairman.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Biotech investment managers search for lucrative opportunities
          Biotech investment managers search for lucrative opportunities

          Fromleft,RodNathan,portfoliomanagerandpartnerofJ.Goldman&Co.;ARKInvestsenioranalystAliUrman;andP

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          Pfizer, Moderna say biotech, pharma drug development is a sprint

          Fromlefttoright,STAT'sDamianGarde;MikaelDolsten,chiefscientificofficerofPfizerresearchanddevelopment